Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model

Atezolizumab (a PD-L1 inhibitor) has shown remarkable efficacy and tolerability in various cancer types. Despite its efficacy and safety, atezolizumab monotherapy has limitations, such as acquired resistance and adverse events. Bojungikki-tang (BJIKT) is an herbal decoction widely prescribed in Asia...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Sung-Yoon, Yi, Jin-Mu, Chun, Jaemoo, Park, Seongwon, Bui, Tham Thi, Yun, Hwi-Yeol, Chae, Jung-Woo, Jeong, Mi-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232755/
https://www.ncbi.nlm.nih.gov/pubmed/37274110
http://dx.doi.org/10.3389/fphar.2023.1181263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232755/
https://www.ncbi.nlm.nih.gov/pubmed/37274110
http://dx.doi.org/10.3389/fphar.2023.1181263

Ejemplares similares